Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer, comprising 52% of patients with primary brain tumors and 20% of all intracranial tumors (between brain and skull). Each year, there are more than 10,000 patients diagnosed with GBM in the United States and over 18,000 in the European Union.
Treatments are mainly palliative and involve a combination of surgery, radiology therapy and chemotherapy. Present pharmacologic agents, including GLIADEL® Wafers, TEMODAR® (temozolomide) and AVASTIN® (bevacizumab), show only modest enhancement in survival with newly diagnosed and primary tumors, with virtually no overall survival or benefit for recurrent tumors. Based on clinical studies, optimal standard of care leads to only a 30% one-year survival rate for those newly diagnosed with GBM and a much lower rate when GBMs recur, which is the case for nearly 98% of patients. Fewer than 5% of GBM patients live beyond three years.
Based on these very poor outcomes, patients with GBM, and particularly recurrent GBM patients, represent an area of significant unmet medical need. Given the individualized nature of interventions and patient treatments, we believe that there is ample opportunity to improve patient outcomes with targeted therapies. As such, Istari is pursuing recurrent GBM as its first target indication with its PVS-RIPO and ADC technologies.
Pre-clinical studies indicate that additional solid tumor types may represent viable tumor targets for PVS-RIPO, including melanoma and breast, prostate, colorectal, lung, pancreatic, ovarian and renal cancer, among others. We expect to initiate programs in conjunction with Duke University Medical Center in melanoma, as well as breast and prostate cancer, as soon as funding allows.
Gliadel® is a registered trademark of Eisai, Inc.
Temodar® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Avastin® is a registered trademark of Genentech, Inc.